Compare AZTA & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZTA | FTRE |
|---|---|---|
| Founded | 1978 | 1996 |
| Country | United States | United States |
| Employees | 2900 | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.4M | 829.3M |
| IPO Year | 1996 | 2023 |
| Metric | AZTA | FTRE |
|---|---|---|
| Price | $17.54 | $13.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $40.60 | $14.06 |
| AVG Volume (30 Days) | 1.3M | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.52 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $593,821,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $6.99 | N/A |
| Revenue Next Year | $5.98 | $3.09 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $15.93 | $3.97 |
| 52 Week High | $41.73 | $18.67 |
| Indicator | AZTA | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 36.28 | 60.60 |
| Support Level | N/A | $8.85 |
| Resistance Level | $32.32 | $18.26 |
| Average True Range (ATR) | 1.18 | 0.84 |
| MACD | -0.52 | -0.08 |
| Stochastic Oscillator | 16.66 | 57.55 |
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.